‘I want to do everything I can to head off dementia’: why demand for the shingles vaccine is soaring

by | Oct 23, 2026 | Health

‘I want to do everything I can to head off dementia’: why demand for the shingles vaccine is soaring

Shingles vaccine bookings have increased significantly across British pharmacies, with some of the heightened demand attributed to research suggesting a potential protective effect against dementia. Boots reported more than a doubling of vaccination appointments over the past year, while Superdrug saw a 41% year-on-year increase. For those under 65 who must pay out-of-pocket, the full two-dose course costs approximately £450, yet many individuals cite dementia prevention as a motivating factor alongside traditional shingles protection.

This trend follows multiple scientific studies exploring a possible link between varicella zoster virus—the pathogen responsible for chickenpox and shingles—and dementia development. Researchers hypothesize that the dormant virus may trigger inflammation and protein accumulation in the brain associated with Alzheimer’s disease. A prominent 2024 study from Stanford University examining a natural experiment in Wales found dementia rates were 8.5% lower in vaccinated women over seven years, suggesting an approximate 20% risk reduction when accounting for vaccination uptake rates. Similar patterns emerged in studies from Australia and Canada.

More recent research from the University of Oxford analyzed over 200,000 vaccinated individuals, comparing outcomes between those receiving Shingrix, a newer vaccine containing viral proteins and an immune-boosting adjuvant, and Zostavax, an older live-attenuated formulation. Over six years, dementia cases proved 17% lower in the Shingrix group, with women experiencing a 22% reduction compared to 13% for men. Researchers emphasized the strength of evidence distinguishing correlation from causation, though the vaccine remains officially approved only for shingles prevention.

Globally, dementia affects nearly 60 million people, with projections exceeding 100 million by 2040. Current treatments for Alzheimer’s disease, the most prevalent form, show limited patient benefit despite clearing amyloid plaques from the brain. Against this backdrop, even modest protective effects from existing vaccines generate considerable public interest and uptake.

Article Attribution | Read More at Article Source

Article summary produced by Claude AI